Form 4: Recursion Pharma Director Sells Shares

Blake Borgeson, a Director at Recursion Pharmaceuticals, Inc., reported the sale of 220,000 shares of Class A Common Stock under a pre-arranged trading plan.

Summary

• Blake Borgeson, a Director of RECURSION PHARMACEUTICALS, INC. (RXRX), reported a transaction involving the company's Class A Common Stock.
• On February 3, 2026, Mr. Borgeson disposed of 220,000 shares of Class A Common Stock.
• The shares were sold at a price of $4.2 per share.
• Following this transaction, Mr. Borgeson directly beneficially owns 6,429,863 shares of Class A Common Stock.
• The transaction was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Borgeson on August 31, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it's an insider sale, the existence of a pre-arranged 10b5-1 plan mitigates the negative signal often associated with such transactions, suggesting it's for personal financial planning rather than a reflection of company performance.

Negatives

• A director sold 220,000 shares of Class A Common Stock, which can sometimes be perceived as a negative signal by investors, even if pre-planned.

Risks

• Insider selling, even under a 10b5-1 plan, could be interpreted by some investors as a lack of confidence in the company's near-term prospects, potentially impacting stock price.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales by directors, are closely watched by the market. While a sale under a Rule 10b5-1 plan indicates a pre-scheduled transaction rather than a reaction to new, non-public information, it still represents a reduction in insider ownership. This type of transaction is common for executives and directors managing personal liquidity and diversification.

Stakeholder Impact

• Shareholders may view the director's sale as a minor negative signal, although the pre-planned nature under a 10b5-1 plan lessens its impact compared to an unplanned sale.

Key Dates

Recommendation

A single Form 4 filing detailing a pre-planned insider sale, while a data point, typically does not warrant a change in investment recommendation. Investors should consider this transaction in the broader context of the company's financial performance, strategic initiatives, and overall market conditions. The 10b5-1 plan suggests a routine, non-event-driven transaction.

Keywords

Recursion Pharmaceuticals, RXRX, Insider Sale, Form 4, Blake Borgeson, Director, Stock Sale, 10b5-1 Plan